OncoSec to Present New Clinical Data at Melanoma Bridge 2014
Nov 5, 2014 11:48:03 GMT
lcd, madamemagoo, and 1 more like this
Post by JHam on Nov 5, 2014 11:48:03 GMT
Here we go. Could be a big day for ONCS. Positive Phase 1 long term data and Phase 2 final data from the melanoma trial (two of the milestones we have been waiting for) are going to be presented Dec. 4th and 5th:
ir.oncosec.com/company-news/detail/1584
OncoSec Medical to Present New Clinical Data at Melanoma Bridge 2014
SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present new data from clinical studies evaluating the Company’s ImmunoPulse immunotherapy in patients with melanoma at Melanoma Bridge 2014. The event is scheduled to take place at the Royal Continental Hotel in Naples, Italy from December 3-6, 2014.
OncoSec’s Chief Medical Officer, Mai H. Le, M.D., commented: “We are looking forward to a great Melanoma Bridge meeting in December and are particularly excited to present both our long-term follow-up data from the Phase 1 trial and the final overall response data from the recently completed Phase 2 study in metastatic melanoma.”
Robert H. Pierce, M.D., Chief Scientific Officer, added “The positive findings from these monotherapy trials really set the stage for our next, critical study in melanoma – testing the combination of IL-12 gene transfer with an anti-PD1/PDL1 therapeutic.”
Data from the two clinical studies evaluating the safety and efficacy of intratumoral electroporation of plasmid interleukin-12 in patients with metastatic melanoma will be featured in separate abstract discussion sessions.
Abstract: Long-term overall survival from a phase I trial using intratumoral plasmid interleukin-12 with electroporation in patients with melanoma (Adil Daud, Kathryn Toshimi Takamura, Tu Diep, Richard Heller, Robert H. Pierce).
When: Thursday, December 4th, 2014. 6:05 PM CET
Abstract: Intratumoral electroporation of plasmid interleukin-12: efficacy and biomarker analyses from a phase 2 study in melanoma (OMS-I100) (Adil Daud, Alain Algazi, Michelle Ashworth, Michael Buljan, Kathryn Toshimi Takamura, Tu Diep, Robert H. Pierce, Shailender Bhatia).
When: Friday, December 5th, 2014. 5:40 PM CET
About Melanoma Bridge 2014
Melanoma Bridge 2014 aims to achieve a broad-based participation by various groups and societies sharing a clinical or basic interest in the immunology and the biology of the cancer microenvironment. The Scientific Board of Melanoma Bridge includes well-known experts from around the world covering a variety of different areas and specialties. The event is being jointly organized by Istituto Nazionale Tumori Fondazione "G. Pascale", Fondazione Melanoma Onlus and Sidra Medical and Research Center, together with the Society for Immunotherapy of Cancer (SITC). For more information, please visit: www.melanomabridge.org
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Investor Relations:
OncoSec Medical Inc.
Jordyn Kopin
855-662-6732
investors@oncosec.com
or
Public Relations:
Dian Griesel, Int’l.
Laura Radocaj
212-825-3210
lradocaj@dgicomm.com
Source: OncoSec Medical Inc.
Released November 5, 2014
ir.oncosec.com/company-news/detail/1584
OncoSec Medical to Present New Clinical Data at Melanoma Bridge 2014
SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present new data from clinical studies evaluating the Company’s ImmunoPulse immunotherapy in patients with melanoma at Melanoma Bridge 2014. The event is scheduled to take place at the Royal Continental Hotel in Naples, Italy from December 3-6, 2014.
OncoSec’s Chief Medical Officer, Mai H. Le, M.D., commented: “We are looking forward to a great Melanoma Bridge meeting in December and are particularly excited to present both our long-term follow-up data from the Phase 1 trial and the final overall response data from the recently completed Phase 2 study in metastatic melanoma.”
Robert H. Pierce, M.D., Chief Scientific Officer, added “The positive findings from these monotherapy trials really set the stage for our next, critical study in melanoma – testing the combination of IL-12 gene transfer with an anti-PD1/PDL1 therapeutic.”
Data from the two clinical studies evaluating the safety and efficacy of intratumoral electroporation of plasmid interleukin-12 in patients with metastatic melanoma will be featured in separate abstract discussion sessions.
Abstract: Long-term overall survival from a phase I trial using intratumoral plasmid interleukin-12 with electroporation in patients with melanoma (Adil Daud, Kathryn Toshimi Takamura, Tu Diep, Richard Heller, Robert H. Pierce).
When: Thursday, December 4th, 2014. 6:05 PM CET
Abstract: Intratumoral electroporation of plasmid interleukin-12: efficacy and biomarker analyses from a phase 2 study in melanoma (OMS-I100) (Adil Daud, Alain Algazi, Michelle Ashworth, Michael Buljan, Kathryn Toshimi Takamura, Tu Diep, Robert H. Pierce, Shailender Bhatia).
When: Friday, December 5th, 2014. 5:40 PM CET
About Melanoma Bridge 2014
Melanoma Bridge 2014 aims to achieve a broad-based participation by various groups and societies sharing a clinical or basic interest in the immunology and the biology of the cancer microenvironment. The Scientific Board of Melanoma Bridge includes well-known experts from around the world covering a variety of different areas and specialties. The event is being jointly organized by Istituto Nazionale Tumori Fondazione "G. Pascale", Fondazione Melanoma Onlus and Sidra Medical and Research Center, together with the Society for Immunotherapy of Cancer (SITC). For more information, please visit: www.melanomabridge.org
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Investor Relations:
OncoSec Medical Inc.
Jordyn Kopin
855-662-6732
investors@oncosec.com
or
Public Relations:
Dian Griesel, Int’l.
Laura Radocaj
212-825-3210
lradocaj@dgicomm.com
Source: OncoSec Medical Inc.
Released November 5, 2014
